Drug intelligence / Profile preview

IM-102

Development stage: Unknown
Lead developer: Integral Molecular
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IM-102 is an investigational monoclonal antibody that functions as an antagonist of the cannabinoid receptor 1 (CB1R). Developed by Integral Molecular, this anti-CB1 antibody is designed to selectively target and block CB1R signaling, a pathway implicated in metabolic, neurologic, and substance use disorders. As a biologic CB1 antagonist rather than a small-molecule ligand, IM-102 aims to achieve high specificity for CB1R with a distinct pharmacologic and safety profile compared with earlier small-molecule CB1 blockers.

Other names: anti-CB1 mAbanti-CB-1 mAbanti-CB 1 mAb

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on IM-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM-102.

Explore the full profile